NervGen Pharma Corp. has appointed Sam Jackson, MD, MBA, as Chief Medical Officer to oversee the clinical development of its lead candidate, NVG-291. Dr. Jackson, a veteran of neuroscience drug development, will lead the execution of the ongoing Phase 3 RESTORE study for spinal cord injury.
The appointment of Sam Jackson, MD, MBA, as Chief Medical Officer strengthens the team executing the Phase 3 RESTORE study for NVG-291, but it carries no hard financial or clinical data point — no results, guidance change, contract value or regulatory decision. Senior hires like this are routine organizational news for a late-stage biotech and rarely move the price on their own.